Press Release

New Chief Medical Officer


Visioneering Technologies Inc. Appoints Ashley Tuan, OD, PhD as Chief Medical Officer


Atlanta, Georgia: US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses (‘NaturalVue MF’) Visioneering Technologies, Inc (ASX: VTI) (‘Visioneering’, ‘VTI’ or ‘the Company’) is pleased to name Kuang-mon (Ashley) Tuan, OD, PhD, FAAO as Chief Medical Officer.


In her new position, Dr. Tuan will be responsible for managing clinical research studies, such as the NaturalVue® (etafilcon A) Multifocal randomized clinical trial for myopia progression control in children, helping identify and develop new products, and leading efforts to communicate findings in key journals and scientific meetings. Dr. Taun will also lead VTI’s Professional Services team as it communicates technical information on products and initiatives to eye care professionals.


“VTI is working hard to build high strategic value in the Company and towards being a profitable independent provider of specialized eye care solutions. Dr. Tuan’s impressive career history highlight our goal to seek out leaders in our industry to help us achieve these goals through innovation in areas such as myopia, and other challenging vision areas,” said Visioneering’s CEO, Stephen Snowdy, PhD. “We are proud to have Dr. Tuan join our team and look forward to the many contributions she will make to our organization as we seek to broaden our profile both geographically and through new product reach.”


Dr. Tuan’s professional career encompasses 27 years experience and includes a strong background in clinical and vision research in areas such as Myopia, Higher Order Aberrations, Presbyopia, Refractive Surgeries and Age-related Macular Degeneration. Most recently, as Vice-President of Mojo Vision, a smart contact lens company, Dr. Tuan focused on medical use cases and contact lens platform product strategy, contact lens system Research & Development with oversight of Clinical, Regulatory, Medical and Professional Affairs. While at CooperVision, Tuan was part of the team that delivered the 3-year study that enabled the launch of myopia control contact lenses, MiSight.


Dr. Tuan is a member of the Association for Research in Vision and Ophthalmology (ARVO), the British Contact Lens Association (BCLA) and is a Fellow of the American Academy of Optometry (FAAO). She obtained her Masters degree in Physiological Optics, her Doctor of Optometry degree from The Ohio State University, and her PhD in Vision Science from the University of California at Berkeley.


“I am thrilled to be joining VTI and returning to the field of Myopia Management. My career has been focused on translating research and technology to advancing various sectors of vision care,” said Dr. Tuan. “The vision care industry is entering a new evolution phase of complex and fascinating period of growth. Together with the VTI team, I am looking forward to the exciting journey of defining an ecosystem and delivering solutions for the Vision Care community with the goal of reducing the risk of myopia-related visual impairment globally.”


To contact Dr. Tuan directly call 1-844-VTI-LENS (1-844-884-5367), or email


Media Contact

Layna Mendlinger





NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day Disposable Soft Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia), and/or presbyopia in normal eyes.

NaturalVue® (etafilcon A) Enhanced Sphere 1 Day Disposable Soft Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) in normal eyes.